![Quan Hong Yuan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Quan Hong Yuan
Directeur Général chez
Shanghai Jianxin Capital Management Co. Ltd.
Fortune : 105 M $ au 31/08/2026
Profil
Quan Hong Yuan is President & Chief Executive Officer at Shanghai Jianxin Capital Management Co. Ltd. since 2010.
Mr. Yuan is Chief Executive Officer at Shanghai Hankang Private Equity Fund Management Co Ltd since 2010.
Mr. Yuan is Non-Executive Director at Sirius Therapeutics since 2023.
Mr. Yuan is Manager at Hankang Biotech III LLC since 2021.
Mr. Yuan is Manager at Pole Star Biotech LLC since 2021.
Former roles include Director at Shenzhen Chipscreen Biosciences Co., Ltd. from 2017 to 2018 and Non-Executive Director at InnoCare Pharma Ltd. from 2019 to 2022.
Education includes an MBA from China Europe International Business School in 2008, a graduate degree from Zhejiang University in 2001, and an undergraduate degree from Zhejiang University in 1996.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
Nanjing Leads Biolabs Co., Ltd.
 Nanjing Leads Biolabs Co., Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company for discovery, development and commercialization of oncology therapies 4,92 % | 02/09/2026 | 9 726 825 ( 4,92 % ) | 90 M $ | 31/08/2026 |
Nanjing Leads Biolabs Co., Ltd.
Nanjing Leads Biolabs Co., Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company for discovery, development and commercialization of oncology therapies 1,08 % | 24/07/2025 | 1 683 194 ( 1,08 % ) | 16 M $ | 31/08/2026 |
Postes actifs de Quan Hong Yuan
| Sociétés | Poste | Début |
|---|---|---|
Shanghai Jianxin Capital Management Co. Ltd. | Directeur Général | 01/09/2010 |
Hankang Capital | Directeur Général | 01/10/2010 |
Hankang Biotech III LLC | Corporate Officer/Principal | 01/01/2021 |
Anciens postes connus de Quan Hong Yuan
| Sociétés | Poste | Fin |
|---|---|---|
| INNOCARE PHARMA LIMITED | Directeur/Membre du Conseil | 31/03/2022 |
| SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. | Directeur/Membre du Conseil | 01/03/2018 |
Formation de Quan Hong Yuan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
99
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
China Europe International Business School
 China Europe International Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zhejiang University
 Zhejiang University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shenzhen Chipscreen Biosciences Co., Ltd.
 Shenzhen Chipscreen Biosciences Co., Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small molecule pharmaceuticals | Health Technology |
InnoCare Pharma Ltd.
 InnoCare Pharma Ltd. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of cancer and autoimmune diseases | Health Technology |
Shanghai Jianxin Capital Management Co. Ltd. | |
Hankang Capital | |
Hankang Biotech III LLC |
